Media center
STATEMENT: FDA says PFAS completely phased out of U.S. food packaging
Statement: Biden administration reins in deadly air pollution
Looking ahead: protecting the climate, nature and consumers in 2024
Contact our media team
Mark Morgenstein
Director of Media Relations, The Public Interest Network [email protected]
Are you a member of the media?
Join our media list
Topic/Campaign
Type
Year in review: PIRG’s 2023 highlights
PIRG, its state groups celebrate national, state, local victories for the public interest
RELEASE: Microsoft offers extended Windows 10 support, with added cost
PIRG campaign prompts tech giant to provide security updates for longer.
Broad coalition of groups urges Energy Department to finalize water heater efficiency standards
Consumer, climate, and health advocates called on the U.S. Department of Energy to promptly finalize water heater efficiency standards.
Release: New consumer guide warns against use of ‘medical credit cards’
Payment method can worsen financial burden on patients already struggling to pay for health care
Updated 2023 mid-hurricane season resource guide: data, resources & interview opportunities
The Atlantic hurricane season lasts from June 1 through November 30. This resource guide can help members of the media cover it more thoroughly and accurately.
NPR: A record number of Americans may fly this summer. Here’s everything you need to know
NPR interviewed PIRG’s Chief Operating Officer for Program Andre Delattre about the troubles of modern air travel.
2023 Wildfire Season coverage guide: data, resources and interview opportunities
The Public Interest Network (which includes PIRG, Environment America and state groups in often-impacted Western and Southwestern states including Alaska, Arizona, California, Colorado, Oregon, Texas and Washington) is sharing information to help contextualize the major environmental, health and consumer concerns posed by the wildfires that will inevitably come this summer.
SCOTUS action will limit generic drug competition
U.S. Supreme Court on Monday declined to review a federal circuit court decision that imperils a critical method that many generic drug makers use to win approval. The court denied a petition of certiorari in Teva Pharmaceuticals USA, Inc. V GlaxoSmithKline LLC, Et. Al., allowing the divided lower court's decision to stand. This action can have dramatically limit competition from lower-priced generic and biosimilar medicines.
Statement: NC bill to reduce plastic waste passes House, moves to Senate
NC biomedical repairers call on legislature to pass medical Right to Repair bill
New bill would protect patient safety and reduce healthcare costs, advocates say